Can prenatal screening reduce the adverse obstetric outcomes related to abnormal placentation?
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
Works matching IS 01973851 AND DT 2014 AND VI 34 AND IP 7
Results: 17
1
2
Can prenatal screening reduce the adverse obstetric outcomes related to abnormal placentation?
- Published in:
- Prenatal Diagnosis, 2014, v. 34, n. 7, p. 613, doi. 10.1002/pd.4423
- By:
- Publication type:
- Article
3
Can the quantity of cell-free fetal DNA predict preeclampsia: a systematic review.
- Published in:
- Prenatal Diagnosis, 2014, v. 34, n. 7, p. 685, doi. 10.1002/pd.4416
- By:
- Publication type:
- Article
4
Overview of low molecular weight heparin for preventative treatment of adverse obstetric outcomes related to abnormal placentation.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
5
Stage-based approach to the management of fetal growth restriction.
- Published in:
- Prenatal Diagnosis, 2014, v. 34, n. 7, p. 655, doi. 10.1002/pd.4412
- By:
- Publication type:
- Article
6
First trimester screening cannot predict adverse outcomes yet.
- Published in:
- Prenatal Diagnosis, 2014, v. 34, n. 7, p. 668, doi. 10.1002/pd.4407
- By:
- Publication type:
- Article
7
First trimester screening can predict adverse pregnancy outcomes.
- Published in:
- Prenatal Diagnosis, 2014, v. 34, n. 7, p. 660, doi. 10.1002/pd.4406
- By:
- Publication type:
- Article
8
Low-dose aspirin for prevention of adverse outcomes related to abnormal placentation.
- Published in:
- Prenatal Diagnosis, 2014, v. 34, n. 7, p. 642, doi. 10.1002/pd.4403
- By:
- Publication type:
- Article
9
Treatment of poor placentation and the prevention of associated adverse outcomes - what does the future hold?
- Published in:
- Prenatal Diagnosis, 2014, v. 34, n. 7, p. 677, doi. 10.1002/pd.4401
- By:
- Publication type:
- Article
10
First-trimester maternal factors and biomarker screening for preeclampsia.
- Published in:
- Prenatal Diagnosis, 2014, v. 34, n. 7, p. 618, doi. 10.1002/pd.4397
- By:
- Publication type:
- Article
11
Role of maternal plasma levels of placental growth factor for the prediction of maternal complications in preeclampsia according to the gestational age at onset.
- Published in:
- Prenatal Diagnosis, 2014, v. 34, n. 7, p. 706, doi. 10.1002/pd.4390
- By:
- Publication type:
- Article
12
Overview of low molecular weight heparin for preventative treatment of adverse obstetric outcomes related to abnormal placentation.
- Published in:
- Prenatal Diagnosis, 2014, v. 34, n. 7, p. 649, doi. 10.1002/pd.4423
- By:
- Publication type:
- Article
13
Biophysical markers for abnormal placentation: first and/or second trimester.
- Published in:
- Prenatal Diagnosis, 2014, v. 34, n. 7, p. 628, doi. 10.1002/pd.4377
- By:
- Publication type:
- Article
14
Screening for abnormal placentation and adverse pregnancy outcomes with maternal serum biomarkers in the second trimester.
- Published in:
- Prenatal Diagnosis, 2014, v. 34, n. 7, p. 635, doi. 10.1002/pd.4370
- By:
- Publication type:
- Article
15
Maternal serum analytes as predictors of IUGR with different degrees of placental vascular dysfunction.
- Published in:
- Prenatal Diagnosis, 2014, v. 34, n. 7, p. 692, doi. 10.1002/pd.4369
- By:
- Publication type:
- Article
16
Umbilical artery Doppler at 19 to 22 weeks of gestation in the prediction of adverse pregnancy outcomes.
- Published in:
- Prenatal Diagnosis, 2014, v. 34, n. 7, p. 711, doi. 10.1002/pd.4367
- By:
- Publication type:
- Article
17
Serum hyperglycosylated human chorionic gonadotrophin at 14-17 weeks of gestation does not predict preeclampsia.
- Published in:
- Prenatal Diagnosis, 2014, v. 34, n. 7, p. 699, doi. 10.1002/pd.4335
- By:
- Publication type:
- Article